pulmonary%20thromboembolism
PULMONARY THROMBOEMBOLISM
Pulmonary embolism is the blockage of the blood vessels in the lungs usually due to blood clots from the veins, especially the veins in the legs and pelvis.
Dyspnea, chest pain, syncope or tachypnea (respiratory rate of ≥20/min) occur in most cases of pulmonary embolism.
Pleuritic chest pain with or without dyspnea is one of the most frequent presentations of this disease.
Syncope or shock are the hallmark signs of central pulmonary embolism and usually result in severe hemodynamic repercussions.
Signs of hemodynamic compromise and reduced heart flow are also usually present.

Principles of Therapy

Parenteral Anticoagulants

General Therapy Principles Regarding Heparin

  • Heparin should be administered in patients w/ intermediate or high clinical probability of PE before imaging studies are performed & in low probability patients once PE is confirmed
  • If PE occurs postoperatively, Heparin therapy should not be started until 12-24 hours after major surgery & after consultation w/ surgeon
    • Treatment could be delayed even longer if there is any evidence of bleeding from the surgical site
  • Both subcutaneous low molecular weight heparin (SC LMWH) or intravenous unfractionated heparin (UFH) short course treatments are recommended for objectively confirmed non-massive PE
    • Either LMWH or UFH is appropriate for the initial treatment of PE

Thrombolysis

General Therapeutic Principles

  • Studies have shown a more rapid improvement in radiographic & hemodynamic abnormalities in acute massive PE patients who received thrombolytic agents & anticoagulant agents over conventional anticoagulant agents alone
    • There was no clinically relevant outcomes for death rate or for the resolution of symptoms

Massive PE

  • The use of thrombolytic therapy in PE should be individualized
    • Patients w/ hemodynamically unstable PE who are at low risk of bleeding are the most appropriate candidates
  • Thrombolytic therapy is recommended in high-risk PE presenting w/ cardiogenic shock &/or persistent arterial hypotension
  • Thrombolytic therapy may also be considered in patients w/
    • Compromised oxygenation
    • Free-floating right ventricular thrombus or patent foramen ovale documented by echocardiography
    • Massive hemodynamically significant PE w/o systemic hypotension or profound hypoxemia

Non-massive PE

  • The use of thrombolytic therapy in non-high-risk patients (hemodynamically stable patients w/ echocardiographic evidence of RV dysfunction) is controversial
    • Further studies are needed to show a clinically relevant improvement in the benefit-risk ratio of thrombolytic treatment over traditional anticoagulant therapy in these patients
  • Thrombolytic therapy should not be used in patients w/ low-risk PE

Pharmacotherapy

Adrenergic Agonists

  • Should be considered for patients w/ low cardiac index & normal blood pressure (BP) or w/ impending hypotension

Dobutamine

  • Considered 1st-line agent to treat right-sided heart failure & cardiogenic shock
  • Affects vasodilatation of both systemic & pulmonary vascular beds, increases myocardial contractility while decreasing right-sided filling pressures

Dopamine

  • Has also been used for hemodynamic support in pulmonary embolism (PE) patients
  • Use may be limited by the development of tachycardia

Epinephrine

  • May be effective when shock complicates acute PE
  • Vasoconstrictor effect similar to Norepinephrine, inotropic effect more due to potent beta1 stimulation rather than beta2 effect, accounting for improved pulmonary vascular resistance

Norepinephrine

  • May be appropriate in acute massive PE when there is profound hypotension
  • Stimulates both alpha-adrenergic (inducing vasoconstriction) & beta1-adrenergic receptors (augmenting cardiac contractility) resulting in improved systemic blood pressure, cardiac output, pulmonary vascular resistance, & right ventricular pressure
  • Combination w/ other vasoactive agents such as Dobutamine needs further evaluation

Nitric Oxide Inhalation

  • May be indicated in patients w/ pulmonary hypertension & a patent foramen ovale
  • Based on clinical studies, may improve the hemodynamic status & gas exchange in patients w/ PE

Parenteral Anticoagulants

Unfractionated Heparin (UFH)

  • Intravenous (IV) UFH treatment in PE is well-established
  • UFH should be considered:
    • As a 1st dose bolus
    • When rapid reversal of effect may be required, as in patients w/ high-risk of bleeding
  • Should be given as initial anticoagulation for patients w/ PE presenting w/ shock or hypotension, also referred to as high-risk PE or clinically massive PE
  • Preferred over LMWH in patients w/ severe renal failure
  • IV UFH has been proven effective in the therapy of PE & deep vein thrombosis (DVT)
    • Studies have shown a reduced mortality rate when UFH has been used to treat VTE disease
    • Recurrence of VTE is unusual when UFH is infused at a rate that prolongs the aPTT >1.5 times the control value & when adequate levels are reached w/in 24 hours
  • IV UFH typically requires hospitalization w/ frequent monitoring & dose adjustment
    • aPTT should be measured 4-6 hours after bolus injection, then 3 hours after each dose adjustment, or once daily when the target therapeutic dose has been attained
  • Heparin-induced thrombocytopenia is a rare but serious complication

Low-molecular-weight heparin (LMWH)

  • LMWH is now preferred over UFH in patients w/ acute non-massive PE
  • A number of studies have shown that LMWH has equal efficacy to UFH in patients w/ non-massive PE
  • Patients w/ symptomatic PE should initially be treated in the hospital because of:
    • Decreased cardiorespiratory reserve
    • Complications
    • Monitoring of international normalized ratio (INR) to guide Warfarin therapy
  • The use of LMWH is safe, effective, may shorten hospital stay & improve the quality of life for patients
  • Monitoring of platelet count is necessary before treatment initiation & on the 5th day, then every 2-3 days if LMWH treatment is continued
  • LMWH is not recommended for high-risk PE w/ hemodynamic instability

Fondaparinux

  • Also a preferred initial treatment for DVT & PE
  • Heparin assay (anti-factor Xa) has been used to monitor effects of Fondaparinux
  • Obtain a platelet count prior to the start of therapy & periodically to check for any bleeding
  • Fondaparinux is not recommended for high-risk PE w/ hemodynamic instability & those w/ severe renal impairment
  • Recommended for patients w/ known history of heparin-induced thrombocytopenia

Duration of Therapy

  • Treatment w/ UFH, LMWH, or Fondaparinux should be continued for at least 5-7 days after the initiation of Warfarin & until therapeutic INR is stable & ≥2 (range: 2.0-3.0) for 2 consecutive days

Oral Anticoagulant

  • Eg Warfarin, Rivaroxaban, Dabigatran etexilate
  • Long-term anticoagulant treatment of PE is for prevention of fatal & nonfatal recurrent venous thromboembolic events & complications

Dabigatran etexilate

  • A direct thrombin inhibitor that effectively prevents thrombin generation
  • Studies have shown that Dabigatran is comparable to Warfarin for the treatment of PE
    • Dabigatran also effectively prevents recurrence of DVT w/ or w/o PE, & bleeding incidences

Rivaroxaban

  • A direct factor Xa inhibitor that effectively prevents thrombin generation
  • An alternative treatment for parenteral anticoagulants in the initial treatment of patients w/ high clinical pretest probability
  • Studies have shown that Rivaroxaban is comparable to Warfarin for the prevention of PE

Warfarin

  • Should be started only when VTE has been reliably confirmed
    • Start on day 1 of Heparin therapy, except in patients w/ suspected hypercoagulable state (Protein C or Protein S deficiency) wherein adequate anticoagulation w/ Heparin is needed before start of treatment to prevent Warfarin-induced skin necrosis or other transient hypercoagulable complications
  • Bolus dose is not effective, therefore it requires at least 5 days to achieve its full effect
    • Thus, it is recommended that Warfarin therapy overlap w/ Heparin at least 5 days until therapeutic INR is stable & ≥2 x 2 consecutive days
  • Therapy w/ Warfarin remains unsatisfactory
    • High rate of major bleeding despite optimal attempts at dose adjustment by INR

Antithrombotics

  • Eg Alteplase (r-tPA), Streptokinase, Urokinase
  • Alteplase (r-tPA)
    • Has comparable thrombolytic capacity to Streptokinase & Urokinase but can be administered for a shorter duration (2 hours)
    • Preferred thrombolytic agent because of its shorter administration time
  • Streptokinase or Urokinase
    • These 2 agents have similar thrombolytic effects in PE & have been shown to resolve PE comparatively at 24 hours & 3x that as seen w/ Heparin alone
    • 12 hours of Urokinase has equivalent thrombolytic efficacy to 24 hours of Streptokinase

Non-Pharmacological Therapy

  • A considerable number of deaths occur w/in the 1st few hours after massive pulmonary embolism (PE) & therefore appropriate supportive therapy could have a major role in pulmonary embolism (PE) w/ circulatory failure

O2 Supplementation

  • May be necessary in patients w/ hypoxemia
  • Consider monitoring of O2 saturation & give supplementary O2 if necessary

Mechanical Ventilation

  • May be needed temporarily in patients who appear toxic & hypoxic
  • Care should be taken to limit its hemodynamic adverse effects
    • Positive intrathoracic pressures induced by mechanical ventilation, may reduce venous return & worsen right ventricular (RV) failure

Hemodynamic Support

Fluid Loading

  • Fluids may be administered initially & cautiously, but other vasoactive therapy should promptly follow
  • Aggressive fluid challenge is not recommended
    • May worsen RV function by causing ventricular overstretch, leading to decreased contractility

Contraindications to Thrombolysis

  • Absolute contraindications to thrombolysis in a life threatening situation are rarely a factor for treatment

Absolute Contraindications to Thrombolysis

  • Active internal bleeding
  • Recent spontaneous intracranial bleeding

Relative Contraindications

  • Ischemic stroke w/in the last 2 months
  • GI bleeding w/in the last 10 days or active peptic ulcer disease
  • Serious trauma w/in the last 15 days
  • Neurosurgery or ophthalmologic surgery w/in the last 1 month
  • Uncontrolled severe hypertension (SBP >180 mmHg, DBP >100 mmHg)
  • Platelet count <10,000/mm3, protime <50%
  • Pregnancy or w/in 1 week postpartum
  • Diabetic hemorrhage retinopathy
  • Major surgery, delivery, open biopsy or puncture of a non-compressible vessel w/in the past 10 days
  • Recent CPR
  • Anemia (hematocrit <30)
  • Bacterial endocarditis
  • Renal disease
  • Liver disease
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
22 May 2017
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.